Signature miRNAs in colorectal cancers were revealed using a bias reduction small RNA deep sequencing protocol

Oncotarget

Volumn 7, Issue 4, 2016, Pages 3857-3872

  Sun, Guihua ^a   Cheng, Ya Wen ^b   Lai, Lily ^a   Huang, Tsui Chin ^b   Wang, Jinhui ^a   Wu, Xiwei ^a   Wang, Yafan ^a   Huang, Yasheng ^a   Wang, Jinghan ^a   Zhang, Keqiang ^a   Hu, Shuya ^a   Yang, Ji Rui ^b   Yen, Yun ^a,b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Colorectal cancer; MicroRNA; miR 143; miR 21; Small RNA deep sequencing

Indexed keywords

APC PROTEIN; K RAS PROTEIN; MICRORNA; MICRORNA 10B; MICRORNA 143; MICRORNA 145; MICRORNA 148A; MICRORNA 192; MICRORNA 194; MICRORNA 200B; MICRORNA 200C; MICRORNA 21; MICRORNA 26A; PROTEIN P53; UNCLASSIFIED DRUG; MESSENGER RNA; TUMOR MARKER;

ADULT; AGED; APC GENE; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENETIC CODE; HUMAN; MALE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; RNA SEQUENCE; SEQUENCE ANALYSIS; TP53 GENE; TUMOR VOLUME; UPREGULATION; CANCER STAGING; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; PROCEDURES; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84957998944     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6460     Document Type: Article

References (40)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108.
2. Norat T, Aune D, Chan D and Romaguera D. Fruits and vegetables: updating the epidemiologic evidence for the WCRF/AICR lifestyle recommendations for cancer prevention. Cancer Treat Res. 2014; 159:35-50.
3. McManus MT. MicroRNAs and cancer. Semin Cancer Biol. 2003; 13:253-258.
4. Michael MZ, SM OC, van Holst Pellekaan NG, Young GP and James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003; 1:882-891.
5. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR and Golub TR. MicroRNA expression profiles classify human cancers. Nature. 2005; 435:834-838.
6. Griffiths-Jones S. miRBase: microRNA sequences and annotation. Curr Protoc Bioinformatics. 2010; Chapter 12:Unit 12 19 11-10.
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
8. Xuan Y, Yang H, Zhao L, Lau WB, Lau B, Ren N, Hu Y, Yi T, Zhao X, Zhou S and Wei Y. MicroRNAs in colorectal cancer: Small molecules with big functions. Cancer Lett. 2015; 360:89-105.
9. Yang X, Zhong J, Ji Y, Li J, Jian Y, Zhang J and Yang W. The expression and clinical significance of microRNAs in colorectal cancer detecting. Tumour Biol. 2015; 36:2675-2684.
10. Orang AV and Barzegari A. MicroRNAs in colorectal cancer: from diagnosis to targeted therapy. Asian Pac J Cancer Prev. 2014; 15:6989-6999.
11. Sun G, Wu X, Wang J, Li H, Li X, Gao H, Rossi J and Yen Y. A bias-reducing strategy in profiling small RNAs using Solexa. RNA. 2011; 17:2256-2262.
12. Fuchs RT, Sun Z, Zhuang F and Robb GB. Bias in ligation-based small RNA sequencing library construction is determined by adaptor and RNA structure. PLoS One. 2015; 10:e0126049.
13. Linsen SE, de Wit E, Janssens G, Heater S, Chapman L, Parkin RK, Fritz B, Wyman SK, de Bruijn E, Voest EE, Kuersten S, Tewari M and Cuppen E. Limitations and possibilities of small RNA digital gene expression profiling. Nat Methods. 2009; 6:474-476.
14. Sun Y, Wang L, Guo SC, Wu XB and Xu XH. Highthroughput sequencing to identify miRNA biomarkers in colorectal cancer patients. Oncol Lett. 2014; 8:711-713.
15. Drusco A, Nuovo GJ, Zanesi N, Di Leva G, Pichiorri F, Volinia S, Fernandez C, Antenucci A, Costinean S, Bottoni A, Rosito IA, Liu CG, Burch A, Acunzo M, Pekarsky Y, Alder H, et al. MicroRNA profiles discriminate among colon cancer metastasis. PLoS One. 2014; 9:e96670.
16. Schee K, Lorenz S, Worren MM, Gunther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA and Flatmark K. Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer. PLoS One. 2013; 8:e66165.
17. Zhang J, Li S, Li L, Li M, Guo C, Yao J and Mi S. Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function. Genomics Proteomics Bioinformatics. 2015; 13:17-24.
18. Srivastava A, Filant J, Moxley KM, Sood A, McMeekin S and Ramesh R. Exosomes: a role for naturally occurring nanovesicles in cancer growth, diagnosis and treatment. Curr Gene Ther. 2015; 15:182-192.
19. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007; 133:647-658.
20. Qi L, Bart J, Tan LP, Platteel I, Sluis T, Huitema S, Harms G, Fu L, Hollema H and Berg A. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer. 2009; 9:163.
21. Talotta F, Cimmino A, Matarazzo MR, Casalino L, De Vita G, D'Esposito M, Di Lauro R and Verde P. An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation. Oncogene. 2009; 28:73-84.
22. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R and Vyzula R. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007; 72:397-402.
23. Borralho PM, Kren BT, Castro RE, da Silva IB, Steer CJ and Rodrigues CM. MicroRNA-143 reduces viability and increases sensitivity to 5-fluorouracil in HCT116 human colorectal cancer cells. Febs J. 2009; 276:6689-6700.
24. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K, Wang G, Ba Y, Zhu L, Wang J, Yang R, Zhang Y, Ren Z, Zen K, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009; 28:1385-1392.
25. Ng EK, Tsang WP, Ng SS, Jin HC, Yu J, Li JJ, Rocken C, Ebert MP, Kwok TT and Sung JJ. MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer. Br J Cancer. 2009; 101:699-706.
26. Takagi T, Iio A, Nakagawa Y, Naoe T, Tanigawa N and Akao Y. Decreased expression of microRNA-143 and-145 in human gastric cancers. Oncology. 2009; 77:12-21.
27. Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J, Chen HY and Sun XF. Clinicopathological significance of microRNA-31,-143 and-145 expression in colorectal cancer. Dis Markers. 2009; 26:27-34.
28. Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K, Nakashima R, Kitade Y and Naoe T. Role of anti-oncomirs miR-143 and-145 in human colorectal tumors. Cancer Gene Ther. 2010; 17:398-408.
29. Kent OA, McCall MN, Cornish TC and Halushka MK. Lessons from miR-143/145: the importance of cell-type localization of miRNAs. Nucleic Acids Res. 2014; 42:7528-7538.
30. Cekaite L, Rantala JK, Bruun J, Guriby M, Agesen TH, Danielsen SA, Lind GE, Nesbakken A, Kallioniemi O, Lothe RA and Skotheim RI. MiR-9,-31, and-182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia. 2012; 14:868-879.
31. Schee K, Boye K, Abrahamsen TW, Fodstad O and Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer. 2012; 12:505.
32. Xu XM, Qian JC, Deng ZL, Cai Z, Tang T, Wang P, Zhang KH and Cai JP. Expression of miR-21, miR-31, miR-96 and miR-135b is correlated with the clinical parameters of colorectal cancer. Oncol Lett. 2012; 4:339-345.
33. Chen T, Yao LQ, Shi Q, Ren Z, Ye LC, Xu JM, Zhou PH and Zhong YS. MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1alpha (FIH-1). Cancer Biol Ther. 2014; 15:516-523.
34. Manceau G, Imbeaud S, Thiebaut R, Liebaert F, Fontaine K, Rousseau F, Genin B, Le Corre D, Didelot A, Vincent M, Bachet JB, Chibaudel B, Bouche O, Landi B, Bibeau F, Leroy K, et al. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wildtype metastatic colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res. 2014; 20:3338-3347.
35. Wu CW, Ng SC, Dong Y, Tian L, Ng SS, Leung WW, Law WT, Yau TO, Chan FK, Sung JJ and Yu J. Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma. Clin Cancer Res. 2014; 20:2994-3002.
36. Kang K, Zhang X, Liu H, Wang Z, Zhong J, Huang Z, Peng X, Zeng Y, Wang Y, Yang Y, Luo J and Gou D. A novel real-time PCR assay of microRNAs using S-Poly(T), a specific oligo(dT) reverse transcription primer with excellent sensitivity and specificity. PLoS ONE. 2012; 7:e48536.
37. Hsu S-D, Tseng Y-T, Shrestha S, Lin Y-L, Khaleel A, Chou C-H, Chu C-F, Huang H-Y, Lin C-M and Ho S-Y. miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions. Nucleic acids research. 2014; 42:D78-D85.
38. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P and Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011; 27:1739-1740.
39. Chen D-T, Hernandez JM, Shibata D, McCarthy SM, Humphries LA, Clark W, Elahi A, Gruidl M, Coppola D and Yeatman T. Complementary strand microRNAs mediate acquisition of metastatic potential in colonic adenocarcinoma. Journal of Gastrointestinal Surgery. 2012; 16:905-913.
40. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR and Lander ES. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:15545-15550.